A Phase 2 Randomized Double-Blind Placebo-Controlled Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adult Patients Previously Treated for CDI

Grants and Contracts Details

StatusFinished
Effective start/end date10/7/112/28/14

Funding

  • ViroPharma Inc: $45,650.00